NIMI
ALNY icon

Natixis Investment Managers International’s Alnylam Pharmaceuticals ALNY Stock Holding History

Natixis Investment Managers International’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,333
Closed -$467K – 41
2018
Q3 		$467K Sell
5,333
-3,860
-42% -$388K 0.02% 485
2018
Q2 		$905K Buy
9,193
+674
+8% +$66.9K 0.05% 302
2018
Q1 		$1.01M Buy
8,519
+3,777
+80% +$487K 0.07% 177
2017
Q4 		$602K Sell
4,742
-2,435
-34% -$306K 0.07% 105
2017
Q3 		$843K Sell
7,177
-7,895
-52% -$674K 0.07% 191
2017
Q2 		$1.2M Buy
+15,072
New +$963K 0.1% 140
2017
Q1 		– Sell
-8,991
Closed -$337K – 392
2016
Q4 		$337K Sell
8,991
-3,698
-29% -$155K 0.03% 292
2016
Q3 		$860K Buy
12,689
+9,991
+370% +$705K 0.09% 152
2016
Q2 		$150K Buy
+2,698
New +$170K 0.02% 352
2015
Q4 		– Sell
-4,515
Closed -$363K – 399
2015
Q3 		$363K Buy
+4,515
New +$502K 0.05% 247
2014
Q3 		– Sell
-1,004
Closed -$63K – 188
2014
Q2 		$63K Hold
1,004
– – 0.01% 198
2014
Q1 		$67K Buy
+1,004
New +$77.7K 0.01% 166

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Natixis Investment Managers International's ALNY Position: Q4 2018 in Review

Natixis Investment Managers International sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2018, closing a stake of 5,333 shares — an estimated $467K sold.

Natixis Investment Managers International first reported a position in ALNY in Q1 2014 and held it in 12 quarters. The position peaked at $1.2M in Q2 2017. 284 funds tracked by Wall St. Rank hold ALNY as of Q4 2018.

  • Natixis Investment Managers International reported no remaining Alnylam Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Natixis Investment Managers International sold 5,333 Alnylam Pharmaceuticals shares in Q4 2018, an estimated $467K.
  • Natixis Investment Managers International first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 12 quarters.
  • Natixis Investment Managers International's Alnylam Pharmaceuticals position peaked at $1.2M in Q2 2017.
  • 284 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2018.

Based on Natixis Investment Managers International's 13F filing for Q4 2018, filed 14 Feb 2019.